Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2016
Event: The Company announced the filing of a US patent application (#62/400557) titled "Treatment of Stroke by Amniotic Fluid Derived Stem Cell Conditioned Media and Products Derived Thereof."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The primary change is the strategic development milestone regarding the new patent application.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The press release furnished as Exhibit 99.1 contains forward-looking statements based on information available as of December 13, 2016.
- Risks: Actual results could differ materially from anticipated results due to various factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent reports.
- Management Commentary: The Company assumes no duty or obligation to update or revise forward-looking statements, though it may do so as warranted or required by law.
Investor Verification Checklist
- Verify the status and scope of US patent application #62/400557.
- Review the full text of the press release (Exhibit 99.1) for specific details on the stroke treatment technology.
- Consult the Form 10-K for the year ended December 31, 2015, to understand the risk factors referenced in this filing.
- Check for subsequent filings to see if the Company has updated its forward-looking statements regarding this patent.